title: Multiple myeloma : recent progress in diagnosis and treatment.
abstract: Multiple myeloma (MM) has been the most intractable hematological disease for many years. Recently, basic and clinical research has advanced remarkably and a new therapeutic strategy has been established. The introduction of high-dose melphalan with autologous stem-cell transplantation and the availability of molecular-targeted novel agents such as immunomodulatory drugs and proteasome inhibitors have dramatically changed the treatment strategies for MM. Achievement of a high response rate resulted in the extension of overall survival, but further research and the development of more multimodality therapeutic approaches is warranted to cure this disease.
authors.affiliation: Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan. chou@niigata-cc.jp
authors.forename: Takaaki
authors.initials: T
authors.lastname: Chou
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use*; D019468:Disease Management; D004334:Drug Administration Schedule; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D008558:Melphalan / Q000494:pharmacology / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D061988:Proteasome Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D061988:Proteasome Inhibitors; D008558:Melphalan